A Multi-center, Parallel-group, Randomized, Double-blind, Placebo-masked, Multiple Dose Trial of Modified-release (MR) and Immediate-release (IR) Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Latest Information Update: 08 Feb 2019
At a glance
- Drugs Tolvaptan (Primary) ; Tolvaptan
- Indications Autosomal dominant polycystic kidney disease
- Focus Pharmacokinetics
- Sponsors Otsuka Pharmaceutical Development & Commercialization
Most Recent Events
- 08 Feb 2019 New trial record
- 07 Jan 2019 Results of population pharmacokinetic analyses and model validation of Tolvaptan from 5 phase II trials (NCT00413777, NCT01210560, NCT01214421 and NCT02160145) published in the Journal of Clinical Pharmacology.